非小细胞肺癌脑转移的靶向治疗进展  

Progress of Targeted Therapy for Brain Metastasis from Non-Small Cell Lung Carcinoma

作　　者：李彩和 胡昌辰[1,2] 程东东 王晓宇[1] 郭建忠[1,2] LI Caihe;HU Changchen;CHENG Dongdong;WANG Xiaoyu;GUO Jianzhong(The Fifth Clinical Medical College,Shanxi Medical University,Taiyuan 030000,China;Dept.of Neurosurgery,Shanxi Provincial People’s Hospital,Taiyuan 030000,China)

机构地区：[1]山西医科大学第五临床医学院,太原030000 [2]山西省人民医院神经外科,太原030000

出　　处：《中国医院用药评价与分析》2022年第4期497-503,共7页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：国家自然科学基金项目(No.30901774);山西省自然科学基金项目(No.2014011038-2);山西省重点研发计划项目(国际合作)(No.201803D421055);山西省留学人员科技活动择优资助项目(No.2018014);山西省卫生健康委科研课题(No.2019021);山西省人民医院省级专项配套经费科研项目(No.sj20019003)。

摘　　要：非小细胞肺癌(NSCLC)脑转移患者预后差,自然中位生存期短。靶向药物的应用可使NSCLC脑转移患者的生存期显著延长。目前已发现的驱动基因中,表皮生长因子受体(EGFR)基因突变的占比最大,间变性淋巴瘤激酶(ALK)融合基因重排的脑转移发生率最高。针对上述2种基因的靶向药物不断被研发,美国国立癌症综合网络(NCCN)指南也推荐了不同的靶向治疗方案。本文结合NCCN指南,综述靶点为EGFR突变和ALK重排的靶向药物研究现状,聚焦药物颅内效应,旨在为上述2种驱动基因阳性的NSCLC脑转移患者的靶向治疗提供用药参考。Patients with brain metastasis from non-small cell lung carcinoma(NSCLC)have poor prognosis and short natural median survival.The application of targeted drugs can significantly prolong the survival of patients with brain metastases from NSCLC.Among the driving genes found so far,epidermal growth factor receptor(EGFR)mutation accounts for the largest proportion,and anaplastic lymphoma kinase(ALK)rearrangement has the highest incidence of brain metastasis.Targeted drugs for the above two genes are constantly being developed,and the National Comprehensive Cancer Network(NCCN)guidelines recommend different targeted treatment options.This paper reviews the current status of research on drugs targeting EGFR mutation and ALK rearrangement based on NCCN guidelines,focusing on the intracranial effects of drugs,with the aim of providing reference for targeted therapy for patients with brain metastases from the above two driving genes.

关 键 词：非小细胞肺癌 脑转移 靶向治疗 表皮生长因子受体 间变性淋巴瘤激酶 

分 类 号：R979.1[医药卫生—药品]